

2022 Regular Session

HOUSE BILL NO. 378

BY REPRESENTATIVE MARINO

1 AN ACT

2 To amend and reenact R.S. 40:964(Schedule II)(A)(1)(introductory paragraph) and to enact
3 R.S. 40:964(Schedule I)(A)(80) through (99), (C)(66), (E)(12), and (F)(29), and
4 (Schedule IV)(D)(15), relative to the Uniform Controlled Dangerous Substances
5 Law; to add certain substances to Schedules I and IV; to provide relative to
6 substances of vegetable origin or chemical synthesis in Schedule II; and to provide
7 for related matters.

8 Be it enacted by the Legislature of Louisiana:

9 Section 1. R.S. 40:964(Schedule II)(A)(1)(introductory paragraph) is hereby
10 amended and reenacted and R.S. 40:964(Schedule I)(A)(80) through (99), (C)(66), (E)(12),
11 and (F)(29), and (Schedule IV)(D)(15) are hereby enacted to read as follows:

12 §964. Composition of schedules

13 Schedules I, II, III, IV, and V shall, unless and until added to pursuant to R.S.
14 40:962, consist of the following drugs or other substances, by whatever official
15 name, common or usual name, chemical name, or brand name designated:

16 SCHEDULE I

17 A. Opiates. Unless specifically excepted or unless listed in another schedule,
18 any of the following opiates, including their isomers, esters, ethers, salts, or salts of
19 isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers,
20 or salts is possible within the specific chemical designation:

21 * * *

22 (80) Phenylfentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide)

- 1 (81) para-methylfentanyl (N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-
2 yl)propanamide)
- 3 (82) Thiofuranylfentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene
4 -2-carboxamide)
- 5 (83) beta-methylfentanyl (N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-
6 yl)propanamide)
- 7 (84) beta-phenylfentanyl (N-(1-phenethylpiperidin-4-yl)-N,3-
8 diphenylpropanamide)
- 9 (85) 2-fluoro-ortho-fluorofentanyl (N-(1-(2-fluorophenethyl)piperidin-4-yl)-
10 N-(2-fluorophenyl)propanamide)
- 11 (86) 4-methylacetylfentanyl (N-(1-(4-methylphenethyl)piperidin-4-yl)-N-
12 phenylacetamide)
- 13 (87) Orthomethylacetylfentanyl (N-(2-methylphenyl)-N-(1-
14 phenethylpiperidin-4-yl)acetamide)
- 15 (88) Orthomethylmethoxyacetylfentanyl (2-methoxy-N-(2-methylphenyl)-N-
16 (1-phenethylpiperidin-4-yl)acetamide)
- 17 (89) Ortho-fluoroacrylfentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-
18 4-yl)acrylamide)
- 19 (90) Fentanyl carbamate (ethyl(1-phenethylpiperidin-4-yl)(phenyl)
20 carbamate)
- 21 (91) para-fluorofuranylfentanyl (N-(4-fluorophenyl)-N-(1-
22 phenethylpiperidin-4-yl)furan-2-carboxamide)
- 23 (92) Isotonitazene (N,N-diethyl-2-[(4-isopropoxyphenyl)methyl]-5-nitro-
24 1H-benzimidazole-1-ethanamine)
- 25 (93) Metonitazene (N,N-diethyl-2-[(4-methoxyphenyl)methyl]-5-nitro-1H-
26 benzimidazole-1-ethanamine)
- 27 (94) Butonitazene (N,N-diethyl-2-[(4-butoxyphenyl)methyl]-5-nitro-1H-
28 benzimidazole-1-ethanamine)
- 29 (95) Flunitazene (N,N-diethyl-2-(4-fluorophenyl)methyl]-5-nitro-1H-
30 benzimidazole-1-ethanamine)

1 (96) Protonitazene (N,N-diethyl-2-[(4-propoxyphenyl)methyl]-5-nitro-1H-
 2 benzimidazole-1-ethanamine)

3 (97) N-pyrrolidino etonitazene (2-[(4-ethoxyphenyl)methyl]-5-nitro-1-
 4 [2-(pyrrolidino-1-yl)ethyl]-1H-benzimidazole)

5 (98) Etodesnitazene (N,N-diethyl-2-[(4-ethoxyphenyl)methyl]-1H-
 6 benzimidazole-1-ethanamine)

7 (99) Metodesnitazene (N,N-diethyl-2-[(4-methoxyphenyl)methyl]-1H-
 8 benzimidazole-1-ethanamine)

9 * * *

10 C. Hallucinogenic substances. Unless specifically excepted or unless listed
 11 in another schedule, any material, compound, mixture, or preparation, which
 12 contains any quantity of the following hallucinogenic substances, or which contains
 13 any of their salts, isomers, or salts of isomers, whenever the existence of such salts,
 14 isomers, or salts of isomers is possible within the specific chemical designation, for
 15 purposes of this Paragraph only, the term "isomer" includes the optical, position, and
 16 geometric isomers:

17 * * *

18 (66) para-methoxymethamphetamine (PMMA)

19 * * *

20 E. Stimulants. Unless specifically excepted, or contained within a
 21 pharmaceutical product approved by the United States federal Food and Drug
 22 Administration, or unless listed in another schedule, any material, compound,
 23 mixture, or preparation which contains any quantity of the following substances
 24 having a stimulant effect on the central nervous system including its salts, isomers,
 25 esters, or ethers and salts of isomers, esters, or ethers whenever the existence of such
 26 salts, isomers, esters, or ethers and salts of isomers, esters, or ethers is possible
 27 within the specific chemical designation:

28 * * *

29 (12) 4,4-dimethylaminorex (4,4-DMAR)

1 F. Synthetic cannabinoids. Unless specifically excepted, or contained within
 2 a pharmaceutical product approved by the United States Food and Drug
 3 Administration, or unless listed in another schedule, any material, compound,
 4 mixture, or preparation, which contains any quantity of a synthetic cannabinoid
 5 found to be in any of the following individual compounds or chemical groups, or any
 6 of those individual compounds or groups which contain any synthetic cannabinoid
 7 salts, isomers, salts of isomers, or nitrogen-heterocyclic analogs, whenever the
 8 existence of such salts, isomers, salts of isomers, or nitrogen-heterocyclic analogs
 9 is possible within the specific compounds or chemical groups:

10 * * *

11 (29) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-B]
 12 pyridine-3-carboxamide [5FCUMYL-P7AICA]

13 * * *

14 SCHEDULE II

15 A. Substances of vegetable origin or chemical synthesis. Unless specifically
 16 excepted or unless listed in another schedule, any of the following substances
 17 whether produced directly or indirectly by extraction from substances of vegetable
 18 origin, or independently by means of chemical synthesis, or by a combination of
 19 extraction and chemical synthesis:

20 (1) Opium and opiate, and any salt, compound, derivative, or preparation of
 21 opium or opiate, excluding apomorphine, thebaine-derived butorphanol, dextropran,
 22 nalbuphine, naldemedine, nalmefene, naloxegol, naloxone, 6β-naltrexol, ~~and~~
 23 naltrexone, and samidorphan, and their respective salts, but including the following:

24 * * *

25 SCHEDULE IV

26 * * *

27 D. Stimulants. Unless specifically excepted or unless listed in another
 28 schedule, any material, compound, mixture, or preparation which contains any
 29 quantity of the following substances, including its salts, isomers, and salts of
 30 isomers:

31 * * *

1
2
3
4
5

(15) Serdexmethylphenidate

* * *

Section 2. The Louisiana State Law Institute is hereby authorized and directed to renumber the substances in R.S. 40:964(Schedule I)(A),(C), and (E) and (Schedule V)(D) to ensure that such substances are in alphabetical order.

SPEAKER OF THE HOUSE OF REPRESENTATIVES

PRESIDENT OF THE SENATE

GOVERNOR OF THE STATE OF LOUISIANA

APPROVED: _____